Cellular Senescence and COVID-19 Long-Hauler Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.

Official Title
-----------------
Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome

Conditions
-----------------
SARS-CoV2 Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Longhauler's Cohort - Inclusion Criteria: Ability to give informed consent or LAR. At least 18 years old. Ability of subject or LAR to read and speak the English language. Positive PCR or antibody test within 12 months of initial study visit. Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome. Exclusion Criteria: Any potential participant who refuses medical record review. Pregnant females. Incarcerated individuals. Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. Control Cohort - Inclusion Criteria: Ability to give informed consent At least 18 years old Ability of subject to read and speak the English language Exclusion Criteria: Known case of COVID-19. Any potential participant who refuses medical record review. Pregnant females. Incarcerated individuals. Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. COVID-19 Control Cohort Inclusion Criteria: Ability to give informed consent. At least 18 years old. Ability of subject to read and speak the English language. Known case of COVID-19. Exclusion Criteria: Known Longhauler's syndrome/Post-COVID Any potential participant who refuses medical record review. Pregnant females. Incarcerated individuals. Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Longhauler's Syndrome Cohort<br>Subject's with longhaulers | |
| Control Cohort<br>Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome | |
| COVID Control Cohort<br>Subjects who have had COVID-19 but no known Longhauler's syndrome | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors | If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs. | 6 months |